Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22883054 | 1.00 | HTR2A (0.56) | HTR2AMAOBL3MBTL1RAB9AMAPT | |
| SCHEMBL12575467 | 0.88 | HTR2A (0.54) | HTR2AMAOBL3MBTL1RAB9AMAPT | |
| SCHEMBL5827968 | 0.81 | HTR2A (0.80) | HTR2AMAOBL3MBTL1RAB9APLA2G4B | |
| SCHEMBL16937928 | 0.80 | HTR2A (0.53) | HTR2AMAOBL3MBTL1RAB9AMAPT | |
| SCHEMBL17583222 | 0.79 | HTR2A (0.43) | HTR2AMAPTKMT2AHDAC1HDAC2 | |
| SCHEMBL28888688 | 0.79 | MAPT (0.56) | RAB9AMAPTNPSR1NPC1KMT2A | |
| SCHEMBL29523967 | 0.79 | MAPT (0.56) | RAB9AMAPTNPSR1NPC1KMT2A | |
| SCHEMBL22883115 | 0.78 | MAPT (0.48) | RAB9AMAPTNPSR1NPC1KMT2A | |
| SCHEMBL14621621 | 0.78 | HTR2A (0.74) | HTR2AMAOBL3MBTL1RAB9APLA2G4B | |
| SCHEMBL18758083 | 0.77 | HTR2A (0.48) | HTR2ARAB9AMAPTNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | Cybrexa 3, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | Cybrexa 3, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11555019-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | Cybrexa 3, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-3996749-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | Cybrexa 3, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | MAP4, MAP2, TUBB3 | HTR2A 4426/4885MAOB 4341/4885L3MBTL1 1636/4885 |
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | MAP4, MAP2, TUBB3 | HTR2A 4426/4885MAOB 4341/4885L3MBTL1 1636/4885 |
| US-11555019-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | MAP4, MAP2, TUBB3 | HTR2A 4426/4885MAOB 4341/4885L3MBTL1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.